Ovid Therapeutics Q3 revenue slightly beats expectations

Reuters

11/12

Ovid <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Q3 revenue slightly beats expectations

Overview

Ovid Therapeutics Q3 revenue slightly beats analyst expectations
Meg Alexander appointed CEO, effective January 2026

Outlook

Ovid plans Phase 2a trial for OV329 in Q2 2026
Company expects OV350 data in Q4 2025
Ovid anticipates OV4071 clinical trial start in Q2 2026

Result Drivers

Research and development expenses were $5.9 million for the third quarter ended September 30, 2025, compared to $7.9 million for the same period in 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Slight Beat*	$132,000	$131,430 (7 Analysts)
Q3 EPS		-$0.17
Q3 Net Income		-$12.16 mln
Q3 Operating Expenses		$12.66 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Ovid Therapeutics Inc is $4.50, about 70% above its November 11 closing price of $1.35

Press Release: ID:nGNX3mxvZJ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582375669"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582375669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582375669?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582375669","market":"us","top_or_hot":-1,"title":"Ovid Therapeutics Q3 revenue slightly beats expectations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 revenue slightly beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Ovid Therapeutics Q3 revenue slightly beats analyst expectations</p></li><li><p>Meg Alexander appointed CEO, effective January 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ovid plans Phase 2a trial for OV329 in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Company expects OV350 data in Q4 2025</p></li><li><p>Ovid anticipates OV4071 clinical trial start in Q2 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses were $5.9 million for the third quarter ended September 30, 2025, compared to $7.9 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Slight Beat*</p></td><td><p>$132,000</p></td><td><p>$131,430 (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.17</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$12.16 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$12.66 mln</p></td><td></td></tr></tbody></table><p>*Applies to a deviation of less than 1%; not applicable for per-share numbers.</p><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Ovid Therapeutics Inc is $4.50, about 70% above its November 11 closing price of $1.35</p></li></ul><p>Press Release: <span>ID:nGNX3mxvZJ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ovid Therapeutics Q3 revenue slightly beats expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOvid Therapeutics Q3 revenue slightly beats expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Q3 revenue slightly beats expectations</title></head><body><p><span>Overview</span></p><ul><li><p>Ovid Therapeutics Q3 revenue slightly beats analyst expectations</p></li><li><p>Meg Alexander appointed CEO, effective January 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ovid plans Phase 2a trial for OV329 in <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2026</p></li><li><p>Company expects OV350 data in Q4 2025</p></li><li><p>Ovid anticipates OV4071 clinical trial start in Q2 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>Research and development expenses were $5.9 million for the third quarter ended September 30, 2025, compared to $7.9 million for the same period in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Slight Beat*</p></td><td><p>$132,000</p></td><td><p>$131,430 (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.17</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$12.16 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$12.66 mln</p></td><td></td></tr></tbody></table><p>*Applies to a deviation of less than 1%; not applicable for per-share numbers.</p><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Ovid Therapeutics Inc is $4.50, about 70% above its November 11 closing price of $1.35</p></li></ul><p>Press Release: <span>ID:nGNX3mxvZJ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OVID","symbol_name":"Ovid Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO0D6:1","article_id":"2582375669","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582375669","pubTimestamp":1762949618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ovid Therapeutics Q3 revenue slightly beats expectationsOverviewOvid Therapeutics Q3 revenue slightly beats analyst expectationsMeg Alexander appointed CEO, effective January 2026OutlookOvid plans Pha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OVID":"Ovid Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Ovid Therapeutics第三季度营收略超预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OVID":0.9},"content_text":"Ovid Therapeutics Q3 revenue slightly beats expectationsOverviewOvid Therapeutics Q3 revenue slightly beats analyst expectationsMeg Alexander appointed CEO, effective January 2026OutlookOvid plans Phase 2a trial for OV329 in Q2 2026Company expects OV350 data in Q4 2025Ovid anticipates OV4071 clinical trial start in Q2 2026Result DriversResearch and development expenses were $5.9 million for the third quarter ended September 30, 2025, compared to $7.9 million for the same period in 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueSlight Beat*$132,000$131,430 (7 Analysts)Q3 EPS-$0.17Q3 Net Income-$12.16 mlnQ3 Operating Expenses$12.66 mln*Applies to a deviation of less than 1%; not applicable for per-share numbers.Analyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Ovid Therapeutics Inc is $4.50, about 70% above its November 11 closing price of $1.35Press Release: ID:nGNX3mxvZJFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}